A 45-percent increase in cancer diagnoses in the U.S. is expected by 2030. Cancer clinical trials play a crucial role in prevention, early detection, treatment, and, ultimately, cancer cures.
Recognizing that clinical trials in the U.S. face administrative and staffing barriers, regulatory constraints, increasing costs, and lagging patient accrual, AACI established the Clinical Research Initiative (CRI) in 2009 as a presidential initiative.
In late 2018, to mark its success and benefits to members, the program was renamed Clinical Research Innovation.
The first AACI CRI Annual Meeting took place in 2009 with fewer than 200 attendees. By 2019, attendance exceeded 430 with 13 exhibitors and 64 posters on display.
View the CRI Progress Report
View Materials From Past CRI Meetings
Last updated April 20, 2020
The CRI Listserv engages nearly 650 subscribers from 82 of AACI's member centers. The listserv is an efficient platform for AACI members to ask questions, receive immediate feedback, and share best practices.
To examine the benefits of establishing a common nomenclature to use for regulatory filing systems, AACI established the Regulatory File Management Working Group in October 2018. The working group is comprised of AACI leadership, members from AACI cancer centers, and other relevant stakeholders who are working together to create a common cancer clinical trial regulatory file nomenclature.
Identify the challenges associated with non-standardized nomenclature
Develop standard nomenclature for trial regulatory use
Develop a site map for storing common documents
Share best practices for site monitoring
The CRI Steering Committee invited cancer centers to participate in a benchmarking survey to learn more about cancer center clinical trials office (CTO) workload, structure and staffing, trial activation timelines, and sources of CTO funding support. The purpose of collecting this information is to allow cancer center members to compare their center with other AACI members.
Eighty-six percent of elgible centers responded to the survey. Data analysis is underway. The next steps will be to send back summary data reports to participating centers and prepare data for publication.
This task force is facilitating collaboration with industry partners to help AACI member cancer centers implement Shared Investigator Platforms (SIP) for clinical trials.
Read the August 2019 AACI Commentary